J&J Looks to Acquire Protagonist to Bolster Pipeline Amid Stelara Competition
Johnson & Johnson is reportedly discussing the purchase of Protagonist Therapeutics. This move could boost J&J's drug portfolio, especially in treatments for immune conditions and blood cancers.